Washington, D.C. — The U.S. Department of Health and Human Services is conducting an investigation into potential links between COVID-19 vaccines and multiple deaths across various age groups. A spokesperson shared this information on Tuesday, adding that more specifics about the targeted age groups for the Food and Drug Administration’s review have yet to be disclosed.
Dr. Marty Makary, the FDA commissioner, previously indicated that the agency was particularly scrutinizing the deaths of young individuals, raising concerns about the safety of these vaccines. Meanwhile, Dr. Vinay Prasad, the agency’s chief medical and scientific officer, circulated a memo last month suggesting a connection between COVID-19 vaccinations and the deaths of at least 10 children who experienced heart inflammation. He also announced intentions to enhance oversight over the vaccine rollout.
These preliminary findings, based on a review of 96 deaths reported between 2021 and 2024, have not undergone peer review or been published in medical journals. The memo did not specify the health statuses of the deceased children or identify the vaccine manufacturers involved in these cases.
In response to growing scrutiny, Moderna reiterated its earlier position, stating that there are no new safety issues regarding its mRNA vaccine, Spikevax, specifically in children or pregnant women. Similarly, Pfizer, which produces another mRNA-based COVID-19 vaccine in collaboration with BioNTech, stressed its commitment to the safety and efficacy of its product.
The investigation takes place against a backdrop of significant policy shifts by Health Secretary Robert F. Kennedy Jr., who has adopted a more restrictive stance on vaccine distribution. Under his new guidelines, access to vaccines has been limited primarily to individuals aged 65 and older and those with pre-existing health conditions.
Kennedy, who has long questioned the safety of vaccines, has made sweeping changes to U.S. vaccination policy. These include the withdrawal of recommendations for the hepatitis B vaccine at birth and cuts in funding for mRNA vaccine initiatives. In a controversial move, he has also linked vaccines to autism, a claim that contradicts established scientific consensus.
As the investigation unfolds, health officials are closely monitoring the situation to ensure public safety while balancing the ongoing vaccination efforts aimed at combating the pandemic. The outcomes of the FDA’s review could have far-reaching implications for vaccine policies and public health strategies. While regulatory agencies work to address these concerns, the overarching goal remains clear: to protect the health and well-being of the population amidst continuing efforts against COVID-19.